Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines

Craven RA, Stanley AJ, Hanrahan S, Totty N, Jackson DP, Popescu R, Taylor A, Frey J, Selby PJ, Patel PM, Banks RE (2004)
PROTEOMICS 4(12): 3998-4009.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Craven, RA; Stanley, AJ; Hanrahan, S; Totty, N; Jackson, DP; Popescu, R; Taylor, A; Frey, JürgenUniBi; Selby, PJ; Patel, PM; Banks, RE
Abstract / Bemerkung
Treatment of patients with malignant melanoma with interferon-alpha achieves a response in a small but significant subset of patients. Currently, although much is known about interferon biology, little is known about either the particular mechanisms of interferon-alpha activity that are crucial for response or why only some patients respond to interferon-alpha therapy. Two melanoma cell lines (MeWo and MM418) that are known to differ in their response to the antiproliferative activity of interferon-alpha, have been used as a model system to investigate interferon-alpha action. Using a proteomics approach based on two-dimensional polyacrylamide gel electrophoresis and mass spectrometry, several proteins induced in response to interferon-alpha have been identified. These include a number of gene products previously known to be type I interferon responsive (tryptophanyl tRNA synthetase, leucine aminopeptidase, ubiquitin cross-reactive protein, gelsolin, FUSE binding protein 2 and hPNPase) as well as a number of proteins not previously reported to be induced by type I interferon (cathepsin B, proteasomal activator 28alpha and alpha-SNAP). Although the proteins upregulated by interferon-alpha were common between the cell lines when examined at the level of Western blotting, the disparity in the basal level of cathepsin B was striking, raising the possibility that the higher level in MM418 may contribute to the sensitivity of this cell line to interferon-alpha treatment.
cytokine; interferon; melanoma
Page URI


Craven RA, Stanley AJ, Hanrahan S, et al. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS. 2004;4(12):3998-4009.
Craven, R. A., Stanley, A. J., Hanrahan, S., Totty, N., Jackson, D. P., Popescu, R., Taylor, A., et al. (2004). Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS, 4(12), 3998-4009.
Craven, RA, Stanley, AJ, Hanrahan, S, Totty, N, Jackson, DP, Popescu, R, Taylor, A, et al. 2004. “Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines”. PROTEOMICS 4 (12): 3998-4009.
Craven, R. A., Stanley, A. J., Hanrahan, S., Totty, N., Jackson, D. P., Popescu, R., Taylor, A., Frey, J., Selby, P. J., Patel, P. M., et al. (2004). Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS 4, 3998-4009.
Craven, R.A., et al., 2004. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS, 4(12), p 3998-4009.
R.A. Craven, et al., “Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines”, PROTEOMICS, vol. 4, 2004, pp. 3998-4009.
Craven, R.A., Stanley, A.J., Hanrahan, S., Totty, N., Jackson, D.P., Popescu, R., Taylor, A., Frey, J., Selby, P.J., Patel, P.M., Banks, R.E.: Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. PROTEOMICS. 4, 3998-4009 (2004).
Craven, RA, Stanley, AJ, Hanrahan, S, Totty, N, Jackson, DP, Popescu, R, Taylor, A, Frey, Jürgen, Selby, PJ, Patel, PM, and Banks, RE. “Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines”. PROTEOMICS 4.12 (2004): 3998-4009.

10 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Protein signatures for survival and recurrence in metastatic melanoma.
Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM., J Proteomics 74(7), 2011
PMID: 21549228
Cancer biomarker discovery: the entropic hallmark.
Berretta R, Moscato P., PLoS One 5(8), 2010
PMID: 20805891
In vitro and in vivo effect of IFNalpha on B16F10 melanoma in two models: subcutaneous (C57BL6J mice) and lung metastasis (Swiss mice).
Martínez Conesa C, Alvarez Sánchez N, Vicente Ortega V, García Reverte J, Pascual Carpe F, Campos Aranda M., Biomed Pharmacother 63(4), 2009
PMID: 19171452
Identification and functional validation of therapeutic targets for malignant melanoma.
Gremel G, Rafferty M, Lau TY, Gallagher WM., Crit Rev Oncol Hematol 72(3), 2009
PMID: 19328713
Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.
Pincelli C, Pignatti M, Borroni RG., Exp Dermatol 18(4), 2009
PMID: 19348000
Primer on the human genome.
Tsai KY, Tsao H., J Am Acad Dermatol 56(5), 2007
PMID: 17437886
Toxicogenomics of A375 human malignant melanoma cells.
Cheng SL, Huang-Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ., Pharmacogenomics 8(8), 2007
PMID: 17716235
Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies.
Tímár J, Mészáros L, Ladányi A, Puskás LG, Rásó E., Cell Immunol 244(2), 2006
PMID: 17433276
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.
Giannakopoulos NV, Luo JK, Papov V, Zou W, Lenschow DJ, Jacobs BS, Borden EC, Li J, Virgin HW, Zhang DE., Biochem Biophys Res Commun 336(2), 2005
PMID: 16139798

67 References

Daten bereitgestellt von Europe PubMed Central.

Interferons in melanoma.
Agarwala SS, Kirkwood JM., Curr Opin Oncol 8(2), 1996
PMID: 8727310
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH., J. Clin. Oncol. 14(1), 1996
PMID: 8558223
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ., Lancet 351(9120), 1998
PMID: 9654256
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K., J. Clin. Oncol. 16(4), 1998
PMID: 9552047
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH., J. Clin. Oncol. 18(12), 2000
PMID: 10856105
Effects of interferons and other cytokines on tumors in animals: a review.
Thomas H, Balkwill FR., Pharmacol. Ther. 52(3), 1991
PMID: 1726476
Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.
Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, Orfanos CE., J. Invest. Dermatol. 95(6 Suppl), 1990
PMID: 2124247
Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma.
Jakschies D, Hochkeppel HK, Horisberger MA, Deicher H, von Wussow P., J. Invest. Dermatol. 95(6 Suppl), 1990
PMID: 1701809
Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta.
Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW., J. Natl. Cancer Inst. 84(15), 1992
PMID: 1378904
Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype.
Worm M, Schadendorf D, Czarnetzki BM., Melanoma Res. 3(1), 1993
PMID: 7682461
Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.
Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr., Proc. Natl. Acad. Sci. U.S.A. 93(15), 1996
PMID: 8755534
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.
Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY., Science 272(5262), 1996
PMID: 8614832
Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line.
Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, Trigo I, Garrido F, Ruiz-Cabello F., Cancer Immunol. Immunother. 47(2), 1998
PMID: 9769120
Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression.
Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S, Platanias LC, Rosen ST., Blood 91(2), 1998
PMID: 9427711
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling.
Ramana CV, Gil MP, Schreiber RD, Stark GR., Trends Immunol. 23(2), 2002
PMID: 11929133
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.
Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ., J. Biol. Chem. 272(45), 1997
PMID: 9353349
Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha.
Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH., Int. J. Cancer 85(5), 2000
PMID: 10699955
Lack of p21waf1 and p27kip1 protein induction by interferon-alpha2a in human melanoma cell lines.
Bearzatto A, Orlandi L, De Marco C, Daidone MG, Zaffaroni N., Melanoma Res. 9(5), 1999
PMID: 10596912
Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC., J. Interferon Cytokine Res. 22(5), 2002
PMID: 12060499
The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line.
Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, Patel PM., Melanoma Res. 13(3), 2003
PMID: 12777975
Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma.
Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L, Rodriguez-Peralto JL, Fernandez-Herrera J, Hernandez A, Fraga J, Dominguez O, Herrero J, Alonso MA, Dopazo J, Piris MA., Am. J. Pathol. 161(5), 2002
PMID: 12414529
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.
Der SD, Zhou A, Williams BR, Silverman RH., Proc. Natl. Acad. Sci. U.S.A. 95(26), 1998
PMID: 9861020
Proteomics: new perspectives, new biomedical opportunities.
Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, Selby PJ., Lancet 356(9243), 2000
PMID: 11095271
Study of therapy resistance in cancer cells with functional proteome analysis.
Poland J, Schadendorf D, Lage H, Schnolzer M, Celis JE, Sinha P., Clin. Chem. Lab. Med. 40(3), 2002
PMID: 12005211
Proteomics reveals protein profile changes in doxorubicin--treated MCF-7 human breast cancer cells.
Chen ST, Pan TL, Tsai YC, Huang CM., Cancer Lett. 181(1), 2002
PMID: 12430184
Study of the development of chemoresistance in melanoma cell lines using proteome analysis.
Sinha P, Poland J, Kohl S, Schnolzer M, Helmbach H, Hutter G, Lage H, Schadendorf D., Electrophoresis 24(14), 2003
PMID: 12874874
Mitofilin is a transmembrane protein of the inner mitochondrial membrane expressed as two isoforms.
Gieffers C, Korioth F, Heimann P, Ungermann C, Frey J., Exp. Cell Res. 232(2), 1997
PMID: 9168817
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect.
Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE., Proteomics 3(8), 2003
PMID: 12923786
Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin.
Haas AL, Ahrens P, Bright PM, Ankel H., J. Biol. Chem. 262(23), 1987
PMID: 2440890
Pericellular cathepsin B and malignant progression.
Roshy S, Sloane BF, Moin K., Cancer Metastasis Rev. 22(2-3), 2003
PMID: 12785001
Interferons: mechanisms of action and clinical applications.
Parmar S, Platanias LC., Curr Opin Oncol 15(6), 2003
PMID: 14624225
A unique set of polypeptides is induced by gamma interferon in addition to those induced in common with alpha and beta interferons.
Weil J, Epstein CJ, Epstein LB, Sedmak JJ, Sabran JL, Grossberg SE., Nature 301(5899), 1983
PMID: 6218412
Molecular cloning and expression of a gamma-interferon-inducible activator of the multicatalytic protease.
Realini C, Dubiel W, Pratt G, Ferrell K, Rechsteiner M., J. Biol. Chem. 269(32), 1994
PMID: 8051173
Primary structures of two homologous subunits of PA28, a gamma-interferon-inducible protein activator of the 20S proteasome.
Ahn JY, Tanahashi N, Akiyama K, Hisamatsu H, Noda C, Tanaka K, Chung CH, Shibmara N, Willy PJ, Mott JD., FEBS Lett. 366(1), 1995
PMID: 7789512
Gamma-interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophages.
Lah TT, Hawley M, Rock KL, Goldberg AL, Goldberg AL., FEBS Lett. 363(1-2), 1995
PMID: 7729559
Identification and cloning of human polynucleotide phosphorylase, hPNPase old-35, in the context of terminal differentiation and cellular senescence.
Leszczyniecka M, Kang DC, Sarkar D, Su ZZ, Holmes M, Valerie K, Fisher PB., Proc. Natl. Acad. Sci. U.S.A. 99(26), 2002
PMID: 12473748
Down-regulation of Myc as a potential target for growth arrest induced by human polynucleotide phosphorylase (hPNPaseold-35) in human melanoma cells.
Sarkar D, Leszczyniecka M, Kang DC, Lebedeva IV, Valerie K, Dhar S, Pandita TK, Fisher PB., J. Biol. Chem. 278(27), 2003
PMID: 12721301

Podgorski, Biochem. Soc. Symp. 70(), 2003
Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma.
Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G., Cancer 91(5), 2001
PMID: 11251949
An intracellular form of cathepsin B contributes to invasiveness in cancer.
Szpaderska AM, Frankfater A., Cancer Res. 61(8), 2001
PMID: 11309313
Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters.
Otto FJ, Goldmann T, Biess B, Lippold A, Suter L, Westhoff U., Oncology 56(3), 1999
PMID: 10202276
Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c.
Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ., J. Clin. Invest. 106(9), 2000
PMID: 11067865
Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor.
Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, Elling F, Leist M, Jaattela M., J. Cell Biol. 153(5), 2001
PMID: 11381085
Differential expression of the liver proteome in senescence accelerated mice.
Cho YM, Bae SH, Choi BK, Cho SY, Song CW, Yoo JK, Paik YK., Proteomics 3(10), 2003
PMID: 14625850

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

PMID: 15449380
PubMed | Europe PMC

Suchen in

Google Scholar